Pharmaceuticals news FT.com

Novo Nordisk shares fall on latest trial results for new obesity drug

Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema

Mar 10, 2025 - 17:03
 0
Novo Nordisk shares fall on latest trial results for new obesity drug
Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema
Read More

Tags:

Previous Article

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgA...

Next Article

Emirati consortium to launch first satellite of Sirb constellation by late 2026,...

Related Posts

GSK struggles to convince market it can deliver on pipeline plans

GSK struggles to convince market it can deliver on pipe...

Feb 22, 2025  0

Novo Nordisk shares jump up on latest weight-loss drug trial results

Novo Nordisk shares jump up on latest weight-loss drug ...

Feb 9, 2025  0

Drugmakers prepare to sue EU over tax to pay for wastewater clean-up

Drugmakers prepare to sue EU over tax to pay for wastew...

Mar 3, 2025  0